Cargando…
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by an autoantibody-mediated deficiency in ADAMTS13. In healthy individuals, ADAMTS13 has a folded conformation in which the central spacer (S) domain interacts with the C-terminal CUB domains. We recently showed that ADAMTS13 adopt...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579268/ https://www.ncbi.nlm.nih.gov/pubmed/34559219 http://dx.doi.org/10.1182/bloodadvances.2021004971 |
_version_ | 1784596405834219520 |
---|---|
author | De Waele, Laure Curie, Alexandre Kangro, Kadri Tellier, Edwige Kaplanski, Gilles Männik, Andres Tersteeg, Claudia Joly, Bérangère S. Coppo, Paul Veyradier, Agnès De Meyer, Simon F. Roose, Elien Vanhoorelbeke, Karen |
author_facet | De Waele, Laure Curie, Alexandre Kangro, Kadri Tellier, Edwige Kaplanski, Gilles Männik, Andres Tersteeg, Claudia Joly, Bérangère S. Coppo, Paul Veyradier, Agnès De Meyer, Simon F. Roose, Elien Vanhoorelbeke, Karen |
author_sort | De Waele, Laure |
collection | PubMed |
description | Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by an autoantibody-mediated deficiency in ADAMTS13. In healthy individuals, ADAMTS13 has a folded conformation in which the central spacer (S) domain interacts with the C-terminal CUB domains. We recently showed that ADAMTS13 adopts an open conformation in iTTP and that patient immunoglobulin G antibodies (IgGs) can open ADAMTS13. Anti-ADAMTS13 autoantibodies in patients with iTTP are directed against the different ADAMTS13 domains, but almost all patients have autoantibodies binding to the cysteine/spacer (CS) domains. In this study, we investigated whether the autoantibodies against the CS and CUB domains can disrupt the S-CUB interaction of folded ADAMTS13, thereby opening ADAMTS13. To this end, we purified anti-CS and anti-CUB autoantibodies from 13 patients with acute iTTP by affinity chromatography. The successfully purified anti-CS (10/13 patients) and anti-CUB (4/13 patients) autoantibody fractions were tested further in our ADAMTS13 conformation enzyme-linked immunosorbent assay to study whether they could open ADAMTS13. Interestingly, all purified anti-CS fractions (10/10 patients) were able to open ADAMTS13. On the other hand, only half of the purified anti-CUB fractions (2/4 patients) opened ADAMTS13. Our finding highlights that anti-CS autoantibodies that open ADAMTS13 are a common feature of the autoimmune response in iTTP. |
format | Online Article Text |
id | pubmed-8579268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-85792682021-11-10 Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP De Waele, Laure Curie, Alexandre Kangro, Kadri Tellier, Edwige Kaplanski, Gilles Männik, Andres Tersteeg, Claudia Joly, Bérangère S. Coppo, Paul Veyradier, Agnès De Meyer, Simon F. Roose, Elien Vanhoorelbeke, Karen Blood Adv Stimulus Report Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by an autoantibody-mediated deficiency in ADAMTS13. In healthy individuals, ADAMTS13 has a folded conformation in which the central spacer (S) domain interacts with the C-terminal CUB domains. We recently showed that ADAMTS13 adopts an open conformation in iTTP and that patient immunoglobulin G antibodies (IgGs) can open ADAMTS13. Anti-ADAMTS13 autoantibodies in patients with iTTP are directed against the different ADAMTS13 domains, but almost all patients have autoantibodies binding to the cysteine/spacer (CS) domains. In this study, we investigated whether the autoantibodies against the CS and CUB domains can disrupt the S-CUB interaction of folded ADAMTS13, thereby opening ADAMTS13. To this end, we purified anti-CS and anti-CUB autoantibodies from 13 patients with acute iTTP by affinity chromatography. The successfully purified anti-CS (10/13 patients) and anti-CUB (4/13 patients) autoantibody fractions were tested further in our ADAMTS13 conformation enzyme-linked immunosorbent assay to study whether they could open ADAMTS13. Interestingly, all purified anti-CS fractions (10/10 patients) were able to open ADAMTS13. On the other hand, only half of the purified anti-CUB fractions (2/4 patients) opened ADAMTS13. Our finding highlights that anti-CS autoantibodies that open ADAMTS13 are a common feature of the autoimmune response in iTTP. American Society of Hematology 2021-11-08 /pmc/articles/PMC8579268/ /pubmed/34559219 http://dx.doi.org/10.1182/bloodadvances.2021004971 Text en © 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
spellingShingle | Stimulus Report De Waele, Laure Curie, Alexandre Kangro, Kadri Tellier, Edwige Kaplanski, Gilles Männik, Andres Tersteeg, Claudia Joly, Bérangère S. Coppo, Paul Veyradier, Agnès De Meyer, Simon F. Roose, Elien Vanhoorelbeke, Karen Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP |
title | Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP |
title_full | Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP |
title_fullStr | Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP |
title_full_unstemmed | Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP |
title_short | Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP |
title_sort | anti-cysteine/spacer antibodies that open adamts13 are a common feature in ittp |
topic | Stimulus Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579268/ https://www.ncbi.nlm.nih.gov/pubmed/34559219 http://dx.doi.org/10.1182/bloodadvances.2021004971 |
work_keys_str_mv | AT dewaelelaure anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT curiealexandre anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT kangrokadri anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT tellieredwige anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT kaplanskigilles anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT mannikandres anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT tersteegclaudia anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT jolyberangeres anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT coppopaul anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT veyradieragnes anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT demeyersimonf anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT rooseelien anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp AT vanhoorelbekekaren anticysteinespacerantibodiesthatopenadamts13areacommonfeatureinittp |